Clonal Hematopoiesis (CH) broadly describes the expansion of hematopoietic stem cells and their progeny that harbor one or more somatic mutations, typically associated with hematologic malignancies. While CH is not a malignancy and occurs naturally with aging, the presence of this clonal population confers an increased risk for several conditions including cardiovascular disease, hematologic malignancies, and shorter survival for patients with solid tumors. This virtual AACR meeting will explore the biology of CH, causative mutations, population-level studies of CH, and its clinical impact. As we learn more about this disease entity, we will convene experts to discuss how to potentially design CH clinical trials and manage drug approvals.
As a top partner of this year’s AACR Virtual Meeting on Clonal Hematopoiesis, we look forward to meeting fellow scientists to discuss the current challenges with characterizing hematologic malignances and how our single-cell DNA and multi-omic analysis solution can help.
